Table 1.
Effects of GL derivatives on EBV replication in superinfected Raji cells
| Compound | EC50 (μM)a | CC50 (μM)b | Therapeutic indexc |
|---|---|---|---|
| (I) | >1000 | >8000 | NDd |
| (II) | >1000 | >8000 | ND |
| (III) | >1000 | >8000 | ND |
| (IV) | >1000 | >1000 | ND |
| (V) | >1000 | >8000 | ND |
| (VI) | 75 ± 15 (90 ± 20) | 1500 ± 100 | 20 |
| (VII) | 65 ± 10 (75 ± 10) | 1200 ± 60 | 18 |
| (VIII) | 30 ± 5 (50 ± 5) | 4800 ± 180 | 160 |
| (IX) | >1000 | >8000 | ND |
| (X) | 95 ± 25 (130 ± 20) | 1400 ± 100 | 15 |
| (XI) | >1000 | >8000 | ND |
| (XII) | 30 ± 5 (45 ± 5) | 2000 ± 80 | 67 |
| (XIII) | 135 ± 35 (175 ± 20) | 4000 ± 160 | 30 |
| (XIV) | >1000 | >8000 | ND |
| (XV) | 25 ± 5 (42 ± 6) | 5000 ± 150 | 200 |
| GL (18β-GL) | 30 ± 5 (38 ± 4) | 4500 ± 160 | 150 |
| GA (18β-GA) | 4 ± 1 (5 ± 1) | 75 ± 10 | 19 |
a
EC50, effective concentration of the compound needed to inhibit EBV genome copy numbers and, in parentheses, EA/VCA expression to 50% of untreated cells.
b
CC50, cytotoxic concentration of the compound that decreased cell viability to 50% of untreated cells determined by MTT. Results represent mean values ± S.D. of three independent experiments.
c
Therapeutic index is defined as the ratio of CC50 to EC50.
d
ND, not determined.